Mrs Kelley Ann Powers, AUD | |
128 Lilly Rd Ne, Suite #202, Olympia, WA 98506-7400 | |
(360) 357-6314 | |
(360) 705-3745 |
Full Name | Mrs Kelley Ann Powers |
---|---|
Gender | Female |
Speciality | Audiologist-hearing Aid Fitter |
Location | 128 Lilly Rd Ne, Olympia, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1346360484 | NPI | - | NPPES |
9058397 | Medicaid | WA | |
7107295 | Medicaid | WA |
Mailing Address | Practice Location Address |
---|---|
Mrs Kelley Ann Powers, AUD 10016 Lookout Dr Nw, Olympia, WA 98502-9713 Ph: (360) 330-8944 | Mrs Kelley Ann Powers, AUD 128 Lilly Rd Ne, Suite #202, Olympia, WA 98506-7400 Ph: (360) 357-6314 |
News Archive
A Web-based interactive anthology will provide psychologists, economists, anthropologists, sociologists and other scientists with the latest research methods and tools to address emerging challenges in public health, such as the obesity epidemic and the rise of chronic diseases such as heart disease.
A team led by University of Saskatchewan (USask) researcher Khan Wahid has been awarded $250,000 from the federal New Frontiers in Research Fund to create a new pill-sized capsule that uses artificial intelligence (AI)-enabled sensing to diagnose gastrointestinal cancers and bleeding earlier and more precisely than is currently possible.
University of Florida researchers have successfully used molecular probes to detect subtle differences in leukemia cells from patient samples, an achievement that could lead to more effective ways to diagnose and treat cancer.
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.
› Verified 1 days ago